AI-generated illustration; not a photograph of the reported event.
- calendar_today October 21, 2026
Cancer Patients Face Setbacks After Policy Change on Drug Funding
Some Ontario cancer patients say they are devastated by the provincial government's decision to tighten rules for out-of-country treatment coverage, a shift that followed a recent court victory by a fellow patient. The policy change has left patients who are recommended for experimental or unavailable therapies in Ontario without financial support from the Ontario Health Insurance Plan (OHIP), despite urgent medical needs.
Stage 4 Patients Denied Promising U.S. Treatments
Sabrina Apitz-Grossman, 31, was diagnosed with a rare synovial sarcoma that has metastasized from her knee to her lungs. Given an initial prognosis of 12 to 18 months to live, she has pursued radiotherapy, chemotherapy, and surgeries, but the cancer remains. Her doctors now recommend Tecelra—a personalized T-cell therapy currently available only in the United States and not approved in Ontario.
Apitz-Grossman applied for OHIP funding to cover the out-of-country treatment but was denied. A subsequent appeal and an application for access under the Case-by-Case Review Program for administration in Toronto were also unsuccessful. She continues to advocate for access, stating, "I so desperately would love to turn 32." The cost of Tecelra is $727,000 US, and while nearly half of suitable patients respond positively, with substantial survival advantages for responders, the expense creates a barrier when provincial funding is denied.
Legal Challenge and Immediate Policy Response
Last month, Alex Shved, a 37-year-old father with stage 4 cancer in a similar situation, won a court challenge against OHIP's denial of funding for his out-of-country treatment in Florida—valued at $600,000 US. His victory briefly offered hope to other patients facing the same obstacles.
However, Ontario Health Minister Sylvia Jones responded to the court outcome by changing OHIP policy. Now, drug treatments will only be funded out of country if they are already provided in Ontario but temporarily unavailable or subject to delays. This new regulation has narrowed eligibility for funding, leaving many patients feeling abandoned by the health system.
Debate Over Costs and Policy Rationale
Minister Jones argued that the updated rules protect patients and taxpayers from "price gouging" and offer a "fair and transparent approach." She cited a potential avoidance of up to $5.2 billion in additional system costs per year—though her office later clarified this figure referred to the theoretical cost if Ontario stopped negotiating prices altogether. Patients like Apitz-Grossman question whether the cost-saving rationale should take precedence over the potential to save lives. "Are we saying that we could save like 5,000 or more people's lives, and they're proud of themselves for not doing that?" she asked.
Premier Doug Ford previously faced scrutiny after the purchase of a $29-million private jet by the government, a point referenced by patients discussing government spending priorities.
Challenges with Drug Approval and Manufacturer Intentions
OHIP maintains that granting repeated out-of-country drug coverage for medications under review in Canada would undermine incentives for manufacturers to participate in the national drug approval process. However, in several cases—including that of Apitz-Grossman—the manufacturers of promising treatments have declared they do not intend to apply for approval in Canada.
Holly Wardlow, 61, was denied access to a medication for her rare liver cancer through the Case-by-Case Review Program. Despite providing letters from the manufacturer confirming no intention to apply in Canada, the funding was still refused. Wardlow and her husband have since incurred costs of $78,000 a month for her infusions, depleting their savings and turning to online fundraising for support. Meanwhile, her tumor is reportedly shrinking with minimal side effects.
Other Patients and Ongoing Advocacy
Kevin Nash, 59, who has metastatic melanoma and sought the same therapy as Shved, was also denied out-of-country funding and finds the government's reasoning unconvincing. "Do you think that [drug companies] care one bit whether Kevin Nash goes to Buffalo for a treatment?" he asked, expressing frustration.
Patients across Ontario continue to call for more flexibility and compassion in drug funding decisions, especially for stage 4 cancer patients with few options left. The debate over OHIP drug funding, the case-by-case review process, and cancer treatment costs remains deeply contentious in both patient and policy circles.
Source: cbc.ca.
